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(n 5 226). The Eczema Area and Severity Index (EASI), the
peak pruritus (PP) numeric rating scale (NRS), and the
Investigator’s Global Assessment (IGA) were assessed. Standard
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Results: Nemolizumab improved EASI, IGA, and/or NRS-itch
scores, with the 30-mg dose being most effective.
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174 SILVERBERG ET ALAbbreviations usedAD: Atopic dermatitisDLQI: Dermatology Life Quality IndexEASI: Eczema Area and Severity IndexEASI50: Greater than 50% improvement in EASI scoreEASI75: Greater than 75% improvement in EASI scoreEASI90: Greater than 90% improvement in EASI scoreEQ5D: EuroQoL 5-DimensionHADS: Hospital Anxiety and Depression ScaleIGA: Investigator’s Global AssessmentITT: Intent to treatLS: Least squareNRS: Numeric rating scalePP: Peak pruritisTCS: Topical corticosteroidTEAE: Treatment-emergent adverse eventNemolizumab is a humanized mAb that targets the IL-31
receptor a subunit; it has been formulated for subcutaneous
injection and studied in patients with atopic dermatitis (AD).1-3
IL-31 is a member of the IL-6 family of cytokines, which are cen-
tral to the progression of chronic disease.4 Recent information has
implicated IL-31 in the pathogenesis of AD.1,5-10 IL-31 is respon-
sible for a distinct transcriptional program in sensory neurons that
causes nerve elongation and branching andmight underly the ten-
dency of patients with AD to experience ‘‘increased sensitivity to
minimal stimuli inducing sustained itch.’’11
Nemolizumab binds to the IL-31 receptor on a spectrum of
cells, including neurons, which is potentially its mechanism in
relieving pruritus.2 IL-31 regulates brain-derived natriuretic pep-
tide in dorsal root ganglions and the skin, thereby regulating cyto-
kine and chemokine release and controlling itch signaling
pathways.12 Thus inhibition of IL-31 and its actions on brain-
derived natriuretic peptide provides a novel therapeutic approach
for AD. From a broader perspective, IL-31 helps drive
TH2-associated inflammation by modulating keratinocyte differ-
entiation and the immune response through stimulation of proin-
flammatory cytokines.13 Increased skin barrier penetration of
allergens and irritants has been shown to accompany IL-31–asso-
ciated alteration of keratinocyte differentiation.13 Furthermore,
IL-31 can induce pathologic remodeling of the skin through
increased epidermal basal cell proliferation, leading to epidermal
thickening, and stimulated transepidermal water loss and addi-
tional impaired skin barrier function.14
Pruritus is the most burdensome symptom of AD and drives the
‘‘itch-scratch cycle,’’ increasing skin barrier damage and resulting
in sleeplessness, fatigue, and poor quality of life.2,15,16 Pruritus
can directly impair psychosocial well-being and quality of life,
leading to increased stress and depressive symptoms.17 Topical
treatments for AD do not control disease, particularly pruritus,
for all patients, and current systemic therapies are associated
with long-term safety concerns.1 There is a core group of patients
for whom treatment options are limited and who need new safe
and efficacious treatments.18
Nemolizumab targets the IL-31 pathway to manage both signs
and symptoms of AD. In patients with moderate-to-severe AD,
nemolizumabmonotherapy (phase 2a study) or combined therapy
with topical corticosteroids (TCSs; phase 1 study) was associatedwith rapid and sustained relief of pruritus and improvement of
dermatitis.1,3 This phase 2b study assessed the efficacy and safety
of nemolizumab in combination with TCSs to determine the
optimal dose and duration of therapy. TCSs were included
because they are commonly used with systemic regimens for
AD.19 Although prior studies of nemolizumab in patients with
AD used a weight-based dosage, this study evaluated a more
patient-centric dosing strategy, including a loading dose to rapidly
achieve steady-state drug concentrations (4 vs 10-12 weeks) and a
fixed dose to allow potential use of a convenient autoinjector. This
mirrors current development trends with biologic agents. We
chose to assess nemolizumab in this more clinically relevant
scenario.
The loading dose and flat dose were selected based on the
clinical pharmacokinetic profile of nemolizumab. The phase 2a
study demonstrated that steady-state concentrations were
achieved at week 16 of treatment without a loading dose.
Pharmacokinetic models showed that fixed doses of 10, 30, and
90 mg were expected to provide similar systemic exposure levels
to those observed in the previous phase 2a study. In addition,
loading doses were added (20 mg for the 10-mg dose and 60 mg
for the 30-mg dose) to rapidly achieve targeted systemic levels
and ensure a fast onset of action.METHODS
The nemolizumab phase 2b study was conducted in North America (the
United States and Canada), Europe (France, Germany, and Poland), and
Australia. This clinical study was conducted in accordance with the protocol,
the Helsinki declaration (1964) and subsequent amendments, and the Inter-
national Conference on Harmonization Good Clinical Practice guidelines and
in compliance with applicable regulatory requirements.Study design
This was a double-blind, randomized, placebo-controlledmulticenter study
of subcutaneous nemolizumab versus placebo. Nemolizumab was adminis-
tered as a loading dose of 20, 60, or 90 mg on day 1, followed by 10, 30, or
90 mg, respectively, every 4 weeks until week 20 (injections at weeks 4, 8, 12,
16, and 20) and a 12-week follow-up period until week 32. All treatment arms
also received background midpotency or low-potency TCSs started at the
screening visit in a standardized regimen and moisturizer (either the subject’s
preferred moisturizer or moisturizer suggested by the investigator).Patient population
Subjects had moderate-to-severe AD, which was defined as an Investiga-
tor’s Global Assessment (IGA) score of 3 or 4, and severe AD–associated
pruritus uncontrolled by topical treatments. Severe pruritus was defined as a
Pruritus Categorical Scale score of severe on at least 3 of the last 7 days before
screening and an average daily peak pruritus (PP) numeric rating scale (NRS)
intensity of 7 or greater for 7 days before the baseline visit. Additional
inclusion criteria were age of 18 years or greater, chronic AD present for 2 or
more years, body surface area involvement of 10% or greater, and an Eczema
Area and Severity Index (EASI) score of 12 or greater. Patients also had a
documented inadequate response to topical treatments within the past
6 months and were currently using TCSs but also agreed to using only
authorized TCSs throughout the study and agreed to use a moisturizer at least
once per day. Additional criteria and definitions of inadequate response to
topical treatments are provided in the supplementary information provided in
this article’s Online Repository at www.jacionline.org.
Rescue therapy was allowed at any time during the study if deemed
medically necessary by the investigator because of significant worsening of
signs/symptoms of AD. It could take the form of a greater potency or greater




10 mg (n 5 55)
Nemolizumab,
30 mg (n 5 57)
Nemolizumab,
90 mg (n 5 57) Total (n 5 226)
Sex
Male 31 (54.4%) 29 (52.7%) 29 (50.9%) 26 (45.6%) 115 (50.9%)
Female 26 (45.6%) 26 (47.3%) 28 (49.1%) 31 (54.4%) 111 (49.1%)
Race
White 45 (78.9%) 38 (69.1%) 40 (70.2%) 44 (77.2%) 167 (73.9%)
Black/African American 8 (14.0%) 3 (5.5%) 10 (17.5%) 8 (14.0%) 29 (12.8%)
Asian 4 (7.0%) 11 (20.0%) 6 (10.5%) 4 (7.0%) 25 (11.1%)
Other 0 3 (5.4%) 1 (1.8%) 1 (1.8%) 5 (2.2%)
Ethnicity
Hispanic/Latino 5 (8.8%) 2 (3.6%) 2 (3.5%) 2 (3.5%) 11 (4.9%)
Non-Hispanic/Latino 52 (91.2%) 53 (96.4%) 55 (96.5%) 55 (96.5%) 215 (95.1%)
Age (y)
Mean (SD) 40.9 (15.01) 35.3 (14.83) 40.2 (16.64) 40.9 (14.95) 39.3 (15.45)
Range 18-72 18-82 18-80 19-77 18-82
Weight (kg)
Mean (SD) 80.58 (18.84) 73.72 (14.63) 76.90 (18.61) 80.49 (22.77) 77.96 (19.05)
Mean EASI score (SD) 26.96 (12.44) 24.80 (10.20) 25.87 (10.53) 24.24 (10.41) 25.48 (10.92)
IGA score
3 (moderate) 38 (66.7%) 37 (67.3%) 39 (68.4%) 37 (64.9%) 151 (66.8%)
4 (severe) 19 (33.3%) 18 (32.7%) 18 (31.6%) 20 (35.1%) 75 (33.2%)
Mean AD involvement of BSA (SD) 45.6 (22.60) 40.4 (15.66) 42.4 (17.10) 37.6 (18.08) 41.5 (18.65)
Weekly PP-NRS score
Mean 6 SD 8.16 6 1.17 8.62 6 1.05 8.22 6 1.39 8.22 6 1.29 8.30 6 1.24
Range 3.6-10.0 5.4-10.0 0.6-10.0 2.4-10.0 0.6-10.0
Weekly average pruritus NRS score
Mean 6 SD 7.52 6 1.52 8.01 6 1.28 7.62 6 1.56 7.76 6 1.39 7.72 6 1.44
Sleep NRS score 7.7 6 1.75 8.2 6 1.27 7.6 6 1.80 7.9 6 1.43 NA
Mean 6 SD SCORAD score 67.90 6 12.33 66.02 6 11.37 67.01 6 11.43 66.04 6 11.33 66.74 6 11.57
Mean DLQI score 17.0 6 6.60 16.5 6 6.41 15.6 6 7.28 16.6 6 7.36 NA
Mean HADS score 12.2 6 8.23 14.6 6 6.79 12.1 6 7.26 14.0 6 8.36 NA
Percentages are based on the number of subjects with a nonmissing value in the respective treatment arm.
BSA, Body surface area; NA, not available.
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phototherapy, or combinations of treatments. Study drug was continued unless
there was a safety concern or rescue with systemic therapies. Subjects who
received rescue therapies were considered treatment failures for the efficacy
analysis.Efficacy and safety assessments
The primary efficacy end point was percentage change from baseline in
EASI score at week 24. Secondary end points were the proportion of subjects
achieving IGA success (IGA clear [0] or almost clear [1]) at week 24; other
assessments at each visit included percentage change in EASI score, the PP-
NRS score, and the proportion of subjects with improvement in PP-NRS
scores of 4 or greater, sleep disturbance NRS scores, change in SCORAD
score, and proportion of subjects achieving EASI score reduction of 50%,
75%, or 90% from baseline at week 24. Standard safety assessments were
performed (specific information about additional safety and other assessments
is provided in the supplementary information in this article’s Online
Repository).
Quality of life was assessed by using the Dermatology Life Quality Index
(DLQI) and EuroQoL 5-Dimension (EQ5D) scales and the Hospital Anxiety
and Depression Scale (HADS). The DLQI is a 10-item questionnaire focusing
on how skin disease affects overall life quality; each question is rated on a
scale of 0 (not at all) to 3 (very much). EQ5D is a 2-part tool, with a visual
analog score and descriptive questions about mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Mental health symptoms
were assessed by using HADS. HADS is a 14-item instrument, with 7
questions each for anxiety and depression. Ratings are from 0 to 3, with a total
score of 0 to 21 for each subscale.Statistical analysis
SAS software (version 9.3; SAS Institute, Cary, NC) was used, and
statistical analyses were performed on the following subject populations: the
intent-to-treat (ITT, all randomized subjects), per-protocol (ITT subjects who
met all major protocol criteria), and safety (ITT subjects with >_1 study drug
application) populations. All efficacy variables were summarized by treatment
at each visit. Continuous data were summarized by using means, medians,
minimum, maximum, and SDs, and categorical variables were summarized by
frequency and percentage for each response category. Primary and secondary
continuous end points were analyzed by using a mixed-effects model for
repeated measures approach, including terms of treatment group and baseline
IGA severity. All categorical end points were analyzed by using the stratified
Cochran Mantel-Haenszel test, and time-to-event data were summarized and
analyzed by using the Kaplan-Meier method. Multiple imputation and last
observation carried forward methodologies were used as sensitivity analyses
to impute missing values. With binary end points, all missing values were
treated as ‘‘nonresponders.’’ All efficacy data, except the observed case, were
set to missing after rescue medication use. Safety analyses were performed on
the safety population. Adverse events were tabulated in frequency tables by
using the System Organ Class and MedDRA preferred terms.RESULTS
Patient population
A total of 226 subjects were included in the ITT analysis, with
group sizes shown in Table I; 225 of these were included in the
safety population. Subject disposition is provided in the supple-
mentary material in this article’s Online Repository. Baseline
FIG 1. Mean percentage change from baseline in EASI scores over time (ITT population).
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ble between groups and are shown in Table I.Efficacy: AD and inflammation
EASI. All nemolizumab doses showed greater improvement in
mean percentage change in EASI score at week 24 than placebo
(Fig 1). At week 24, the greatest difference from baseline was
seen with the 30-mg nemolizumab dose (268.8% vs 252.1%,
least-square [LS] mean reduction for placebo; P 5 .016).
A greater statistically significant difference was observed at
week 16 with the 30-mg dose (266.8% vs 243.1%, P < .01).
Proportions of subjects reaching greater than 50% (EASI50),
75% (EASI75), and 90% (EASI90) improvement in EASI score
from baselinewere also analyzed (Fig 2). Therewere significantly
more responders in all nemolizumab treatment groups at most
study visits, with best response rates occurring in the 30-mg
dose group. At week 24, EASI50 was achieved in 66.7% versus
43.9% of subjects in the 30-mg nemolizumab versus placebo
groups (P 5 .014), EASI75 was achieved in 45.6% versus
26.3% (P 5 .034), and EASI90 was achieved in 29.8% versus
10.5%, respectively (P 5 .011). At week 16, EASI50 was
achieved in 59.6% versus 36.8% of subjects in the 30-mg nemo-
lizumab versus placebo groups (P5 .016), EASI75 was achieved
in 49.1% versus 19.3% (P <_ .001), and EASI90 was achieved in
33.3% versus 8.8%, respectively (P 5 .001).
IGA success. The proportion of subjects with IGA success
over time is shown in Fig 3. Performance in the 30- and 90-mg
nemolizumab treatment groups was very similar until week 12,
after which the 30-mg nemolizumab dose was superior to the
other nemolizumab doses. By week 24, 36.8% of subjects in the
30-mg nemolizumab dose achieved IGA success compared with21.1% in the placebo group (P5 .06); at week 16, 33.3% of sub-
jects receiving 30 mg of nemolizumab versus 12.3% of patients
receiving placebo achieved IGA success (P 5 .008).
SCORAD. At week 24, all 3 doses improved SCORAD scores
compared with placebo, with the greatest difference in the 30-mg
nemolizumab group. The LS mean absolute change in SCORAD
score at week 24 was225.0 for the placebo group compared with
234.6 (P 5 .016) for the 10-mg nemolizumab group, 237.8
(P 5 .001) for the 30-mg nemolizumab group, and 232.5
(P 5 .058) for the 90-mg nemolizumab group.Efficacy: pruritus
The LS mean percentage change in PP-NRS score is presented
in Fig 4, A. All doses of nemolizumab were associated with a
rapid decrease in pruritus scores, with statistically significant dif-
ferences from placebo starting as early as week 1. By week 2,
scores with all nemolizumab doses were greater than those with
placebo (P <_ .001). The most marked effects on PP scores were
seen in the 30-mg nemolizumab arm compared with the placebo
arm (267.3% vs235.8% at week 24,P <.001). The proportion of
subjects with improvement in weekly average PP-NRS scores of 4
or greater from baselinewas significantly greater in the nemolizu-
mab groups versus the placebo group beginning at week 1, when
17.5% of subjects in the 30-mg nemolizumab dose responded
compared with 5.3% in the placebo group (Fig 4, B).Efficacy: Additional parameters
Sleep. The LS mean percentage change in weekly average
sleep disturbance NRS score at week 24 was267.5%with 10 mg
of nemolizumab, 274.8% with 30 mg of nemolizumab, and
FIG 2. Proportion of EASI 50%, 75%, and 90% responders (ITT population).
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placebo (P <_.001 for all). As shown in Fig 5, a statistically signif-
icant difference from placebo was apparent as early as week 1
with all nemolizumab doses.
Quality-of-life assessments. Nemolizumab positively
affected quality of life, as assessed by using the DLQI and the
visual analog scale section of the EQ5D. DLQI scores decreased
significantly in all nemolizumab groups (P <_.001) compared with
the placebo group by week 2 and were greater than those in the
placebo group at 12 weeks in the 30-mg group (P 5 .043). At
week 24, DLQI scores were 4.8 in the 10-mg nemolizumab group
(mean,211.6-point change; P5 .018), 4.9 in the 30-mg nemoli-
zumab group (mean, 210.5-point change; P 5 .022), and 5.6 in
the 90-mg nemolizumab group (mean, 210.9-point change)
compared with 8.5 in the placebo group (mean, 28.6-point
change). The change from baseline in overall EQ5D index score
at week 24 was not significantly different for any nemolizumab
group versus the placebo group, although there were positive
trends in specific dimensions. Therapy with 30 mg of nemolizu-
mabwas associated with significantly superior effects onmobility
(P 5 .038), and the 10-mg dose was superior to placebo in
mobility (P 5 .083), self-care (P 5 .043), and pain/discomfort
(P 5 .036). Changes in visual analog scale scores were signifi-
cantly different for the 10- and 30-mg doses (P 5 .023 and
.047, respectively).
Mental health symptoms. Mean HADS scores were
comparable among groups at baseline and by week 24 had
decreased by a mean of27.1 points in the 10-mg nemolizumab
group, 24.3 points in the 30-mg nemolizumab group, 24.6
points in the 90-mg nemolizumab group, and24.2 points in theplacebo group. Nemolizumab did not have a significantly
different effect on absolute scores on the HADS Anxiety
subscale at week 12 or 24. There were significant differences
from baseline on the HADS Depression subscale at week 24 in
the 10-mg (P 5 .007) and 30-mg (P 5 .048) nemolizumab
groups. Similarly, significant differences were not apparent in
the group of subjects with HADS Anxiety subscores of 11 or
greater or those with HADS Depression subscores of 11 or
greater at baseline.
Use of background TCSs. The use of medium- and low-
potency TCSs during the treatment period was greater in the
placebo group than in all nemolizumab groups at each monthly
checkpoint. The total mean use of TCSs from baseline to week
24 was 139.88 g in the 10-mg nemolizumab group, 167.53 g in
the 30-mg nemolizumab group, and 163.43 g in the 90-mg
nemolizumab group compared with 232.75 g in the placebo
group. Note that subjects who received rescue treatment or
discontinued the studywere excluded from all TCS use analyses.
The majority of subjects used medium-potency TCSs, and
placebo-treated subjects used almost twice the amount
compared with the nemolizumab group. There was a 30% to
40% reduction in TCS use in the nemolizumab groups versus the
placebo group.
Use of rescue medication. Rescue medication was
required during the treatment period by a total of 34 subjects; 6
in the 10-mg nemolizumab group, 7 in the 30-mg nemolizumab
group, 8 in the 90-mg nemolizumab group, and 13 in the placebo
group. As shown in Table II, use of both topical and systemic
rescue medications were more common in the placebo group
compared with the nemolizumab groups.
FIG 3. Proportion of subjects achieving IGA success (clear/almost clear plus 2-grade improvement).
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A total of 185 patients had at least 1 adverse event, and the
number of treatment-emergent adverse events (TEAEs) was
similar in the placebo and all nemolizumab groups. Nemolizumab
at all doses was well tolerated, with few serious or severe adverse
events; serious TEAEs were reported in 3 (5.5%) of the subjects
receiving 10 mg of nemolizumab, 2 (3.5%) subjects in each of the
30- and 90-mg nemolizumab arms, and 1 (1.8%) placebo-treated
subject. Severe TEAEs occurred in 6 (10.7%) subjects of the
placebo group, 3 (5.5%) subjects of the 10-mg nemolizumab
group, 5 (8.8%) subjects of the 30-mg nemolizumab group, and 2
(3.5%) subjects of the 90-mg nemolizumab group.
There were few adverse events leading to discontinuation (2 in
the 30-mg group, 4 in the 10-mg group, and 7 in the 90-mg group
vs 4 in the placebo group). A summary of the TEAEs occurring in
5% or more subjects is shown in Table III. Selected TEAEs of in-
terest are shown in Table IV.
In subjects with a history of asthma, a greater incidence of
asthma events was observed with nemolizumab in a dose-
dependent fashion. All asthma events were mostly mild in
severity, and there were no de novo cases of asthma associated
with nemolizumab. One severe event was observed in the
90-mg nemolizumab arm. All events were reversible under treat-
ment. There was a low incidence of peripheral edema observed in
both placebo-treated (n 5 2, 3.6%) and nemolizumab-treated
(n5 8, 4.7%) patients, with no serious cases. Overall, occurrence
of the selected TEAEs of interest was acceptable and comparable
in the nemolizumab and placebo groups.
Clinical laboratory data showed no significant changes in liver
enzymes (alanine aminotransferase, aspartate aminotransferase,
blood urea nitrogen, or alkaline phosphatase) through week 24.However, 2 subjects treated with nemolizumab (one in the
10-mg arm and the other in the 90-mg arm) discontinued early
because of increased creatine kinase levels. There were no
signals of effect on C-reactive protein, electrolyte, cholesterol,
or glucose levels.DISCUSSION
This study demonstrated that treatment with nemolizumab
resulted in rapid improvement in AD lesions, as assessed by
EASI and IGA scores, when compared with placebo. In
addition to improvements in inflammatory signs of AD, all
assessments of pruritus showed a highly significant, fast-onset,
and sustained effect of nemolizumab. The primary end point,
percentage change in EASI score at week 24, was statistically
significant versus placebo for the 30-mg nemolizumab dose
(P 5 .016) and borderline statistically significant for the 10-mg
dose (P 5 .051). Although effects on itch and skin lesions have
a separate timeline, data from this study clearly demonstrate a
reduction in skin lesions and a greater improvement in pruri-
tus. All doses except the 90-mg dose showed improvements
in IGA response rates to week 24. Response after week 16
does not appear to increase but remained within expected vari-
ability. A similar observation can be made for the 90-mg dose
with slightly greater variability, which is likely due to a greater
rate of missing responses in this group. The data from this
study did not demonstrate a significant dose-response relation-
ship between the 10- and 90-mg doses for clinical efficacy end
points; this has been observed with other recent drug candi-
dates, most recently with omalizumab.20-23 Therefore the
dose-response profile of the phase 2b study was further
FIG 4. A, LS mean percentage change in PP-NRS scores from baseline to week 24 (ITT population). B, Pro-
portion of subjects with an improvement of weekly average PP-NRS scores of 4 or greater (ITT population).
Any subjects with missing visit or rescue dosing were treated as nonresponders.
FIG 5. Change in sleep NRS scores over time.
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10 mg (n 5 55)
Nemolizumab,
30 mg (n 5 55)
Nemolizumab,
90 mg (n 5 55) Total (n 5 226)
Subjects with >_1 rescue medication and/or
procedure
During treatment period 13 (22.8%*) 6 (10.9%) 7 (12.3%) 7 (14.0%) 34 (15.0%)
During follow-up period 4 (7.0%) 4 (7.3%) 5 (8.8%) 6 (10.5%) 19 (8.4%)
Topical rescue medication (no.) 23 10 9 8 50
Systemic rescue medication (no.) 7 3 1 2 13
The treatment period is defined as from the date of randomization to the date of week 24 (for completers) or 4 weeks after the last study drug injection (for subjects who
discontinued the study drug early). The follow-up period is defined as from the date of week 24 (for completers) or 4 weeks after the last study drug injection (for subjects who
discontinued study drug early) to the date of week 32/the final visit. Rescue medication data are for the treatment period only.
*Percentage of all rescue medication (topical and systemic).
TABLE III. TEAEs occurring in 5% or greater by system organ class and preferred term, all causes (safety population)
Placebo (n 5 56)
Nemolizumab
10 mg (n 5 55) 30 mg (n 5 57) 90 mg (n 5 57) All (n 5 169)
>_1 TEAE 43 (76.8%) 47 (85.5%) 47 (82.5%) 48 (84.2%) 142 (84%)
Infection and infestation 23 (41.4%) 34 (61.8%) 34 (59.6%) 34 (59.6) 102 (60.4%)
Nasopharyngitis 12 (21.4%) 18 (32.7%) 14 (24.6%) 13 (22.8%) 45 (26.6%)
URTI 1 (1.8%) 4 (7.3%) 6 (10.5%) 4 (7%) 14 (8.3%)
Gastroenteritis 0 0 3 (5.3%) 4 (7%) 7 (4.1%)
Sinusitis 0 3 (5.5%) 3 (5.3%) 1 (1.8%) 7 (4.1%)
Oral herpes 1 (1.8%) 2 (3.6%) 1 (1.8%) 3 (5.3%) 6 (3.6%)
UTI 3 (5.4%) 3 (5.5%) 1 (1.8%) 2 (3.5%) 6 (3.6%)
Rhinitis 3 (5.4%) 0 3 (5.3%) 1 (1.8%) 4 (2.4%)
Herpes infection 5 (8.9%) 4 (7.3%) 3 (5.3%) 5 (8.7%) 12 (7.1%)
Skin and subcutaneous tissue disorders 20 (35.7%) 18 (32.7%) 23 (40.4%) 23 (40.4%) 64 (37.9%)
Atopic dermatitis 18 (32.1%) 12 (21.8%) 14 (24.6%) 16 (28.1%) 42 (24.9%)
Dry skin 0 0 3 (5.3%) 0 3 (1.8%)
Respiratory, thoracic, and mediastinal disorders 7 (12.5%) 6 (10.9%) 13 (22.8%) 12 (21.1%) 31 (18.3%)
Asthma event 1 (1.8%) 2 (3.6%) 7 (12.3%) 10 (17.5%) 19 (11.2%)
Cough 2 (3.6%) 1 (1.8%) 3 (5.3%) 2 (3.5%) 6 (3.6%)
UTI, Urinary tract infection; URTI, upper respiratory tract infection.
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models. The dose-response fit with an maximum response
(Emax) or maximum inhibition (Imax model), and the maximum
nemolizumab effect was observed at serum concentrations
close to the observed serum concentration for the 30-mg
dose (data not shown).
Week 16 data are presented to facilitate comparisons with
the majority of AD studies; however, the week 24 end point
was important to better illustrate how nemolizumab performs
over a longer period of time. There was also statistically
significant separation from placebo in secondary end points,
including IGA response, EASI50, EASI75, EASI90, PP-NRS,
sleep NRS, and multiple quality-of-life domains, with the
greatest differences seen at week 16 and with the 30-mg dose
showing superior results to the 3 doses (10, 30, and 90 mg)
tested. Further studies will use week 16 as the primary end
point, which is consistent with most other clinical trials of new
therapies in patients with AD.
The efficacy shown in this study was greater than the results
found in the nemolizumab phase 2a study at 12 weeks,
particularly with the 30-mg dose. The phase 2a study was a
study of nemolizumab monotherapy administered on a weight-
based dosing schedule versus placebo.2 The current data bring
new information about the efficacy of nemolizumab in AD withuse of a fixed dose of nemolizumab plus a loading dose at base-
line, for a longer duration, and in combination with back-
ground (low-potency and midpotency) TCSs. Rapid inhibition
of pruritus in patients with AD is an important treatment
goal. Pruritus relief is expected to contribute to breaking the
‘‘itch-scratch cycle’’ and thus improve the skin condition in pa-
tients with AD. In the nemolizumab phase 2b study, steady-
state condition was achieved by week 4 because of loading
doses of 20 and 60 mg administered in the 10- and 30-mg study
arms, respectively. For the 90-mg arm, steady state was
reached at approximately week 16 of treatment, which is in
full accordance with phase 2a results. It is our opinion that
the use of a loading dose to achieve a more rapid steady state
and a fixed dose improved the effects of nemolizumab on the
inflammatory aspects of AD while retaining the expeditious
reduction in patients with pruritus seen in earlier studies. There
was a relatively high response rate in the placebo arm, which
mirrors the normal TCS response; we believe that this is not
a confounder for the study but rather would more closely
mimic usual clinical practice should nemolizumab be approved
in the management of AD. The study population in the trial
represents a difficult-to-treat population in patients with AD;
these patients are in need of new therapeutic options. Given
the pivotal role of IL-31, it was hypothesized that patients




10 mg (n 5 55)
Nemolizumab,
30 mg (n 5 55)
Nemolizumab,
90 mg (n 5 55)
All nemolizumab
groups (n 5 169)
No. of selected TEAE 74 75 77 74 226
Subjects with selected TEAEs 31 (55.4%) 37 (67.3%) 37 (64.9%) 37 (64.9%) 112 (66.3%)
AD exacerbation 9 (16.1%) 3 (5.5%) 7 (12.3%) 7 (12.3%) 17 (10.1%)
Injection-related reaction 5 (8.9%) 1 (1.8%) 2 (3.5%) 2 (3.5%) 5 (3%)
Local 3 (5.4%) 1 (1.8%) 1 (1.8%) 1 (1.8%) 3 (1.8%)
Systemic 2 (3.6%) 1 (1.8%) 0 1 (1.8%) 2 (1.2%)
Peripheral edema 2 (3.6%) 2 (3.6%) 4 (7.0%) 2 (3.5%) 8 (4.7%)
Skin infection 7 (12.5%) 7 (12.7%) 9 (15.8%) 6 (10.5%) 22 (13%)
Nonskin infection 21 (37.5%) 31 (56.4%) 31 (54.4%) 31 (54.4%) 93 (55%)
Headache 7 (12.5%) 6 (10.9%) 4 (7.0%) 4 (7.0%) 14 (8.3%)
Subjects with selected serious TEAEs 0 1 (1.8%) 2 (3.5%) 2 (3.5%) 5 (3.0%)
Serious AD exacerbation 0 0 1 (1.8%) 0 1 (0.6%)
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incorporated into the study design to more closely mimic clin-
ical realities.
There was a slightly greater incidence of TEAEs and serious
TEAEs with nemolizumab compared with placebo. There was no
imbalance in the incidence of skin infections between the active
and placebo groups, but there was a greater incidence of nonskin
infections with nemolizumab versus placebo. Notably, these
infections were primarily nasopharyngitis, upper respiratory tract
infections, and gastroenteritis. A dose-dependent increase in
asthma events in patients with pre-existing asthma was reported,
with mostly mild and very few moderate events that were
manageable and reversible. All events were observed in subjects
with pre-existing asthma, and treatment was adjusted to the
course of the disease; most of the cases were mild, with peak
expiratory flow decreased in 13 of 24 cases. Some of these events
might have occurred because effective treatment with nemolizu-
mab led to improved overall well-being and increased activity
levels that, in turn, triggered asthma symptoms. Some of the cases
of worsening might have been caused by respiratory tract
infections, and it is reassuring that there were no de novo cases
of asthma associated with nemolizumab. This safety profile is
consistent with that reported by Ruzicka et al,2 except that exac-
erbation of AD occurred more frequently in the placebo group in
our study, whereas it occurred more often in the nemolizumab
groups in the earlier study. In addition, greater rates of peripheral
edema in the nemolizumab groups2 were not found in this study.
Study limitations include a small sample size because it was a
phase 2b study. This makes it difficult to interpret some of the rare
safety events.
In conclusion, of the 3 doses evaluated, the 30-mg every
4-week dose of nemolizumab was the most effective and was
associated with the greatest overall efficacy on AD clinical signs
and pruritus. Treatment with nemolizumab achieved fast onset
and sustained effect on pruritus. Nemolizumab had an acceptable
safety profile.
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d There are patients with moderate-to-severe AD refractory
to topical therapies who have limited treatment options.
d Nemolizumab is a humanized mAb to the IL-31 receptor
a.
d IL-31 has broad actions as a proinflammatory and immu-
nomodulatory cytokine, linking the immune and neural
systems to induce pruritus in patients with AD.
d Nemolizumab monotherapy is effective in patients with
AD, with a notable marked rapid effect on pruritus and
an acceptable safety profile.
d This placebo-controlled, double-blind study evaluated
nemolizumab with concomitant use of TCSs in patients
with moderate-to-severe AD and severe pruritus.
d Nemolizumab had a significant and clinically relevant ef-
fect on cutaneous signs of AD compared with placebo, as
assessed based on EASI and IGA scores, with a rapid and
sustained effect on pruritus.
d This study provides confirmation of the importance of IL-
31 inhibitors in the management of AD.REFERENCES
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